Elicio Therapeutics (ELTX)
NASDAQ:ELTX
Top Page
Elicio Therapeutics
(NASDAQ:ELTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$11.00
▲(1.48% Upside)
Action:ReiteratedDate:03/13/26
The score is primarily held down by weak financial performance (zero revenue, ongoing losses, heavy cash burn, and a leveraged/fragile balance sheet). Technicals provide partial support with price trading above key moving averages and neutral momentum, while valuation remains constrained by a negative P/E and no dividend yield.
Positive Factors
Differentiated R&D Platform
Elicio's focus on targeted delivery and lymph-node targeting represents a structural technical differentiation in cancer vaccines. Such a platform can improve immune activation and trial success probabilities, create licensing or partnership optionality, and sustain competitive advantage if clinical efficacy is demonstrated.
Negative Factors
No Commercial Revenue
Zero revenue means the business lacks commercial cash generation and is entirely dependent on financing to fund R&D and operations. Over a 2–6 month horizon this structurally increases dilution and execution risk, as program advancement must be financed rather than sustained by product cash flows.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated R&D Platform
Elicio's focus on targeted delivery and lymph-node targeting represents a structural technical differentiation in cancer vaccines. Such a platform can improve immune activation and trial success probabilities, create licensing or partnership optionality, and sustain competitive advantage if clinical efficacy is demonstrated.
Read all positive factors
Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$186.72M
Dividend YieldN/A
Average Volume (3M)77.23K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth17.36%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding18,396,074
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-219.55
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
$17.33Price Target Upside59.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Elicio Therapeutics Business Overview & Revenue Model
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccin...
How the Company Makes Money
null...
Elicio Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 28.31M |
| Gross Profit | -1.13M | -1.18M | -1.17M | -1.06M | 27.08M |
| EBITDA | -36.59M | -50.27M | -32.97M | -23.55M | -51.92M |
| Net Income | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
Balance Sheet | |||||
| Total Assets | 25.86M | 28.18M | 27.15M | 22.66M | 96.51M |
| Cash, Cash Equivalents and Short-Term Investments | 18.56M | 17.62M | 12.89M | 7.80M | 88.76M |
| Total Debt | 14.51M | 26.04M | 6.92M | 7.48M | 4.66M |
| Total Liabilities | 24.23M | 39.49M | 15.77M | 13.75M | 15.01M |
| Stockholders Equity | 1.64M | -11.31M | 11.37M | 8.91M | 81.51M |
Cash Flow | |||||
| Free Cash Flow | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Operating Cash Flow | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Investing Cash Flow | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Financing Cash Flow | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
Elicio Therapeutics Technical Analysis
Positive
10.84
Price Trends
10.39
Positive
9.29
Positive
9.62
Positive
Market Momentum
-0.12
Positive
51.80
Neutral
35.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Positive. The current price of 10.84 is above the 20-day moving average (MA) of 10.84, above the 50-day MA of 10.39, and above the 200-day MA of 9.62, indicating a bullish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 51.80 is Neutral, neither overbought nor oversold. The STOCH value of 35.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELTX.
Elicio Therapeutics Risk Analysis
Elicio Therapeutics disclosed 35 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elicio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $243.95M | 4.04 | 55.68% | ― | -88.47% | -1658.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $186.72M | -3.95 | -977.67% | ― | ― | 17.36% | |
50 Neutral | $237.69M | -2.69 | -656.82% | ― | ― | 3.70% | |
40 Underperform | $79.76M | ― | 13.30% | ― | 448.44% | ― |
* Healthcare Sector Average
ELTX
Elicio Therapeutics
10.84
5.92
120.33%
CGEN
Compugen
2.76
1.45
110.69%
MCRB
Seres Therapeutics
8.58
-4.69
-35.32%
MIST
Milestone Pharmaceuticals
2.00
1.17
140.96%
ACTU
Actuate Therapeutics, Inc.
1.82
-6.18
-77.25%
Elicio Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Elicio Therapeutics Launches New $100 Million ATM Program
Neutral
Mar 16, 2026
On March 16, 2026, Elicio Therapeutics entered into a new at-the-market equity offering program of up to $100 million in common stock through B. Riley Securities, JonesTrading Institutional Services and Ladenburg Thalmann, giving the biotech flexi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.